The United States Food and Drug Administration (FDA) closed the month of September with a series of landmark decisions that significantly expand the therapeutic landscape for endocrine-related disorders. These regulatory actions include the first-ever approval for a rare genetic condition known as MCT8 deficiency, the authorization of a once-weekly basal insulin for type 2 diabetes, and the granting of priority review for a new indication for a dual neurokinin receptor antagonist aimed at improving the quality of life for breast cancer survivors. These developments represent a shift toward more specialized, patient-centric treatment modalities that address long-standing unmet medical needs across both rare and prevalent conditions.
A Breakthrough for Rare Disease: The Approval of Emcitate
On September 28, the FDA granted approval to Emcitate (tiratricol) tablets for oral suspension, marking the first available treatment for peripheral thyrotoxicosis in patients suffering from MCT8 deficiency. Also known as Allan-Herndon-Dudley syndrome (AHDS), MCT8 deficiency is an ultra-rare, X-linked genetic disorder that primarily affects males. The condition is characterized by a mutation in the SLC16A2 gene, which provides instructions for the monocarboxylate transporter 8 (MCT8) protein.
The biological implications of this deficiency are devastating. Under normal conditions, the MCT8 transporter is responsible for shuttling thyroid hormones across the blood-brain barrier and into neural cells. In patients with this condition, the transporter is non-functional, leaving the brain in a state of local hypothyroidism while thyroid hormones—specifically triiodothyronine (T3)—accumulate to toxic levels in the blood. This imbalance results in "peripheral thyrotoxicosis," where the rest of the body suffers from an overabundance of thyroid hormone while the brain is starved of it.
Clinical manifestations of MCT8 deficiency include severe intellectual disability, an inability to sit or walk independently, limited or absent speech, and chronic metabolic stress. The excess hormone in the blood places an immense burden on the cardiovascular system, often leading to rapid heart rates (tachycardia) and elevated blood pressure.
Dr. Hylton V. Joffe, Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA’s Center for Drug Evaluation and Research, noted that the primary challenge of treating this condition has historically been the inability to bypass the broken transporter. Emcitate functions by utilizing a thyroid hormone analog, tiratricol, which is capable of entering cells through alternative pathways that do not require the MCT8 protein. This mechanism allows the drug to normalize blood thyroid levels and alleviate the systemic symptoms of the disease.
The FDA’s decision was supported by data from two pivotal clinical studies, including a randomized, placebo-controlled trial (NCT05579327). The results demonstrated that patients treated with Emcitate experienced significant reductions in serum T3 levels and improvements in cardiovascular markers. Given the severity of the disease and the lack of existing therapies, Emcitate was granted several expedited statuses, including Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations.
Addressing the "Unmet Need" in Breast Cancer Care: Lynkuet Priority Review
Parallel to the rare disease breakthrough, the FDA accepted a supplemental New Drug Application (sNDA) for Lynkuet (elinzanetant) on September 28, granting it Priority Review. This application seeks a new indication for the treatment of moderate to severe vasomotor symptoms (VMS)—commonly referred to as hot flashes—specifically in women undergoing endocrine therapy for hormone receptor-positive (HR+) breast cancer.
In the United States, breast cancer remains the most common cancer diagnosis among women, with HR+ cases accounting for approximately 70% of the total. Standard care for these patients involves endocrine therapy (ET), such as tamoxifen or aromatase inhibitors, which are typically prescribed for five to ten years to prevent cancer recurrence. However, these life-saving treatments frequently induce severe VMS, which can be more intense than natural menopausal symptoms.
Currently, there are no FDA-approved non-hormonal treatments specifically indicated for VMS caused by endocrine therapy in this population. This gap often leads to poor medication adherence or the premature discontinuation of cancer treatment. Elinzanetant operates as a dual antagonist of both neurokinin 1 (NK-1) and neurokinin 3 (NK-3) receptors. These receptors are located in the hypothalamus, the area of the brain responsible for thermoregulation. By modulating these pathways, Lynkuet aims to stabilize body temperature without the use of exogenous hormones, which are generally contraindicated in HR+ breast cancer patients.
The sNDA is supported by the Phase III OASIS-4 trial, which focused on the safety and efficacy of elinzanetant in this specific cohort. Dr. Kristie Baisden of Bayer emphasized that the Priority Review status underscores the urgency of providing these patients with a viable management strategy for their symptoms. If approved, Lynkuet would offer a first-in-class option that bridges the gap between oncology and endocrine symptom management.
Revolutionizing Diabetes Management: The Arrival of Weekly Insulin
In a move affecting millions of Americans, the FDA approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe) on September 24. Onswik is a once-weekly basal insulin indicated for adults with type 2 diabetes. This approval marks a significant shift in the daily routine of diabetes management, which has traditionally required once- or twice-daily injections of basal insulin to maintain steady blood glucose levels.
Diabetes affects approximately one in eight Americans, the vast majority of whom have type 2. Projections suggest that by 2030, over 510 million people globally will be living with the condition. For many, the "burden of treatment"—specifically the frequency of injections—acts as a barrier to optimal glycemic control. Onswik is engineered to provide a slow, steady release of insulin over a seven-day period, potentially improving patient compliance and quality of life.
The approval was predicated on the QWINT Phase 3 clinical trial program, which involved more than 3,400 participants. Across the trials, Onswik demonstrated non-inferiority in reducing A1C levels when compared to established daily basal insulins, such as insulin glargine and insulin degludec. The safety profile was found to be comparable to daily alternatives, though the FDA issued a clear contraindication for patients with type 1 diabetes due to a heightened risk of severe hypoglycemia.
Kenneth Custer, Executive Vice President at Lilly Cardiometabolic Health, stated that the development of a weekly insulin reflects a century-long commitment to transforming diabetes care. Onswik’s approval in the U.S. follows similar regulatory successes in Europe, Mexico, and Japan, signaling a global trend toward long-acting, reduced-frequency biologics. The drug will be available in the U.S. market in the coming months via the KwikPen delivery system, offered in two different concentrations to accommodate various dosing needs.
Chronology of Regulatory Milestones
The flurry of activity in the final week of September highlights a coordinated effort by the FDA to address diverse sectors of endocrinology.
- September 24: FDA approves Onswik (insulin efsitora alfa-gobe) for type 2 diabetes, providing a once-weekly alternative to daily basal injections.
- September 28: FDA approves Emcitate (tiratricol), the first-ever treatment for MCT8 deficiency, providing a path forward for patients with Allan-Herndon-Dudley syndrome.
- September 28: FDA grants Priority Review to Lynkuet (elinzanetant) for VMS associated with endocrine therapy in breast cancer patients, setting the stage for a potential approval in early 2026.
Clinical Data and Safety Profiles
For healthcare providers and patients, the safety data of these new therapies remains a primary focus.
In the case of Emcitate, the most frequently reported adverse effects included diarrhea, vomiting, rash, and excessive sweating. Because it is a thyroid hormone analog, the FDA warned that it should not be used in conjunction with other thyroid medications.
For Onswik, the safety concerns mirror those of traditional insulins: hypoglycemia (low blood sugar), injection site reactions (lipodystrophy), weight gain, and allergic reactions. However, the convenience of a once-weekly dose must be weighed against the long half-life of the drug; if a patient experiences hypoglycemia, the effects of the long-acting insulin may persist longer than those of a daily dose.
The data for Lynkuet from the OASIS trials suggest a favorable safety profile for a non-hormonal agent. By targeting the neurokinin receptors rather than the estrogen receptors, the drug avoids the potential risks associated with hormone replacement therapy in women with a history of hormone-sensitive cancers.
Implications for the Future of Endocrinology
The broader implications of these approvals are twofold. First, they demonstrate the FDA’s increasing reliance on "accelerated" and "priority" pathways to bring drugs for rare and high-need conditions to market. The use of Breakthrough Therapy and Orphan Drug designations for Emcitate shows a regulatory willingness to work with smaller patient populations where traditional large-scale trials are impossible.
Second, the move toward "reduced-burden" therapies, such as weekly insulin and non-hormonal hot flash treatments, suggests that the pharmaceutical industry is prioritizing patient experience alongside clinical efficacy. For type 2 diabetics, the reduction from 365 injections a year to 52 represents a massive shift in the daily management of their disease. For breast cancer survivors, the ability to manage debilitating side effects without compromising their oncological treatment could lead to higher survival rates through better therapy adherence.
As these medications move from the laboratory and regulatory halls into clinical practice, the focus will shift to accessibility and real-world outcomes. For now, the end of September stands as a pivotal moment for the endocrine community, offering new hope for patients ranging from those with ultra-rare genetic conditions to those managing the most common chronic diseases in the world.
